카지노 : On September 10th, CAR-T therapy expert Curocell, led by CEO Gunsoo Kim, announced the formalization of a strategic partnership through the signing of a Memorandum of Understanding (MOU) with Genscript Probio, headed by CEO Patrick Liu. The collaboration aims to advance the development of next-generation CAR-T therapies, with a specific focus on the manufacturing of viral vectors.
주식 : Under this agreement, both entities will engage in a comprehensive strategic collaboration encompassing the research, development, and clinical trials of CAR-T therapies. Viral vectors, integral to CAR-T therapies, serve as virus-based delivery systems for transferring genetic material into cells. The surge in demand for viral vectors aligns with the expanding gene therapy and CAR-T therapy markets.